CCR5 and neoplasm: Thus, blocking CCL5-CCR5 interaction (using CCR5 inhibitor maraviroc, blocking CCL5 expression, using anti-CCR5 antibody or CCL5-neutralizing antibody) can reduce the number and immunosuppressive potential of tumor invasive TAMs, inhibit tumor metastasis and improve the survival rate of tumor-bearing mice [34, 40–42].